China fast-tracks Israeli epilepsy treatment

Israel’s D-Pharm has obtained fast track status from the China’s Food and Drug Administration (CFDA) for its epilepsy treatment, DP-VPA. D-Pharm is jointly developing the treatment in China with its local partner, Jiangsu NHWA. DP-VPA has completed a first Phase II clinical trial.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *